The emergence of Retatrutide ZPHC, at a concentration of 120mg, is creating considerable excitement within the weight loss community. This novel dual GIP and GLP-1 receptor medication suggests to offer impressive improvements in fat reduction compared to existing therapies. Preliminary clinical s